Sign in

UNCY on Nasdaq

Unicycive Therapeutics, Inc.

Unicycive Therapeutics, Inc. is an American pharmaceutical preparations company based in Los Altos.1 Its shares trade on Nasdaq under the symbol UNCY.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with Karuna Therapeutics, Polomar Health Services, Inc. or Summit Therapeutics, or pick any stock.

  • TickerUNCY on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersMountain View, California1
  • Incorporated inDE2
  • Business address1975 W. El Camino Real, Suite 204, Mountain View, Ca 940402
  • Filer category, Emerging growth company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

2,100 highest prescribers are responsible for half of the prescriptions written for PLTs annually.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2023

-3077.6%Operating margin4
-4525.0%Net margin4
-29.0%Revenue growth, 20234
-$18.3MFree cash flow4

Where the money goes

Where each dollar of revenue went, fiscal 2023

  • Research and development99¢$12.9M
  • Interest1¢$82.0K

Out of $675.0K in revenue.4 The company lost money this year.

Financial statements

Revenue54$675.0K in 2023−29% since 2022
0$250.0K$500.0K$750.0K$1.0M2022: $951.0K$951.0K20222023: $675.0K$675.0K2023−29%
Operating income6754-$20.8M in 2023+928% since 2020
-$30.0M-$20.0M-$10.0M02020: -$2.0M-$2.0M20202021: -$9.0M-$9.0M2021+344%2022: -$18.1M-$18.1M2022+101%2023: -$20.8M-$20.8M2023+15%
Net income6754-$30.5M in 2023+1249% since 2020
-$40.0M-$30.0M-$20.0M-$10.0M02020: -$2.3M-$2.3M20202021: -$10.0M-$10.0M2021+342%2022: -$18.1M-$18.1M2022+80%2023: -$30.5M-$30.5M2023+69%

Every line of the income statement as filed: the last 2 fiscal years, latest first.10

Period ending2025-12-312024-12-31
Research and development$9.1M$20.0M
General and administrative$20.4M$12.1M
Total operating expenses$29.5M$32.1M
Loss from operations-$29.5M-$32.1M
Interest income$1.0M$1.3M
Interest expense-$71.0K-$71.0K
Change in fair value of warrant liability$2.0M-$5.8M
Total other income (expenses)$3.0M-$4.6M
Net loss-$26.6M-$36.7M
Unrealized loss on marketable securities, net-$1.0K
Net comprehensive loss-$26.6M-$36.7M
Dividend to Series B-1 preferred stockholders-$1.1M
Net loss attributable to common stockholders-$26.6M-$37.8M
Net loss per share attributable to common stockholders, basic (in Dollars per share)-$1.67-$5.65
Net loss per share attributable to common stockholders, diluted (in Dollars per share)-$1.67-$5.65
Weighted-average shares outstanding used in computing net loss per share, basic (in Shares)15.9M shares6.7M shares
Weighted-average shares outstanding used in computing net loss per share, diluted (in Shares)15.9M shares6.7M shares

Compare Unicycive Therapeutics, Inc. with another company

Corporate structure

Unicycive Therapeutics, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Unicycive Therapeutics, Inc.

  • Unicycive Therapeutics, Inc. Mountain View, California

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Unicycive Therapeutics, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$138.0K10 Dec 31, 2025$114.0K10 Dec 31, 2024+21.1%
Accumulated depreciation$72.0K10 Dec 31, 2025$39.0K10 Dec 31, 2024+84.6%
Property and equipment, net$66.0K10 Dec 31, 2025$75.0K10 Dec 31, 2024−12.0%
Operating-lease assets (leased space)$108.0K10 Dec 31, 2025$645.0K10 Dec 31, 2024−83.3%

Real estate and locations

ItemLatestA year beforeChange
Area of land10,734 sq ft10 Nov 30, 20252,581 sq ft10 Jun 28, 2024+315.9%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$29.2M10 Dec 31, 2025$26.1M10 Dec 31, 2024+11.7%
Marketable securities, current$12.1M10 Dec 31, 2025

Properties, in its own words

Our principal address is 4300 El Camino Real, Suite 210, Los Altos, CA 94022. We believe our facilities are adequate to meet our current needs, although we may seek to negotiate new leases or evaluate additional or alternate space for our operations. We believe appropriate alternative space would be readily available on commercially reasonable terms.

Item 2 of the 10-K filed Mar 30, 2026.3

Leadership

Who has led Unicycive Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Board members and other officers (6)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Chief Financial OfficerJohn Townsend named Mar 13, 2023 to Mar 20, 202417
  • Chief Executive Officer, President and Chairman of the Board of DirectorsShalabh Gupta named Mar 13, 2023 to Mar 20, 202417
  • DirectorJohn Ryan named Mar 13, 2023 to Mar 20, 202417

Timeline

  1. Sep 29, 20268-K Executive or director change; Other events18
  2. Sep 28, 20268-K Other events19
  3. Aug 12, 20268-K Results of operations20
  4. Jul 2, 20268-K Other events21
  5. Jun 22, 20268-K Shareholder vote22
  6. Jun 5, 20268-K Entered a material agreement23
  7. May 12, 20268-K Results of operations24
  8. Apr 6, 20268-K Executive or director change25
  9. Mar 30, 20268-K Results of operations26
  10. Nov 14, 20258-K Other events27
  11. Nov 12, 20258-K Results of operations28
  12. Oct 28, 20258-K Results of operations; Other events29

Calendar

Coming up

  1. Nov 11, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.39) a share, on Nov 12, 2025.30

When it reported results

  1. Aug 12, 2026Reported quarterly or annual results20
  2. May 12, 2026Reported quarterly or annual results24
  3. Mar 30, 2026Reported quarterly or annual results26
  4. Nov 12, 2025Reported quarterly or annual results28
  5. Oct 28, 2025Reported quarterly or annual results29
  6. Aug 14, 2025Reported quarterly or annual results31
  7. Jun 30, 2025Reported quarterly or annual results32
  8. May 14, 2025Reported quarterly or annual results33

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

254 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 70 major events, 59 insider forms, 50 large holders, 2 private raises, 53 other. The latest 20:

  1. Oct 1, 20263 EDGAR
  2. Sep 29, 20268-K CURRENT REPORT EDGAR
  3. Sep 28, 20268-K CURRENT REPORT EDGAR
  4. Aug 14, 2026SCHEDULE 13G/A EDGAR
  5. Aug 14, 2026SCHEDULE 13G/A EDGAR
  6. Aug 12, 20268-K CURRENT REPORT EDGAR
  7. Aug 12, 202610-Q QUARTERLY REPORT EDGAR
  8. Jul 30, 2026SCHEDULE 13G EDGAR
  9. Jul 28, 20264/A EDGAR
  10. Jul 28, 20264/A EDGAR
  11. Jul 8, 2026SCHEDULE 13G/A EDGAR
  12. Jul 2, 20268-K CURRENT REPORT EDGAR
  13. Jul 1, 2026144 EDGAR
  14. Jun 22, 2026DEFA14A CURRENT REPORT EDGAR
  15. Jun 22, 20268-K CURRENT REPORT EDGAR
  16. Jun 15, 2026EFFECT EDGAR
  17. Jun 15, 20264/A EDGAR
  18. Jun 15, 20264/A EDGAR
  19. Jun 15, 20264/A EDGAR
  20. Jun 15, 20264/A EDGAR

The 254 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

1 open-market trades by officers, directors and large owners since October 2021: 1 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
May 16, 2022Schiller BrigitteDirectorBuy15,000$0.83$12.4KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Shalabh GuptaM.D.,53$572.0K$2.4M48
2025Pramod GuptaPh.D.,$468.0K$1.0M48
2025Doug Jermasek,65$363.0K$481.2K48
2024Chief Executive Officer$572.0K$2.4M48
2024Executive VP Pharmaceutical and Business Operations$468.0K$1.2M48
2024Executive VPCorporate Strategy$363.0K$873.3K48

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Money received by year$80.2M 2023–2024
Money received by yearMoney received by year, 2023–2024: $80.2M in all. Private raises (Form D) $80.2M.$0$20M$40M$60M2023 · Private raises (Form D): $30.2M20232024 · Private raises (Form D): $50.0M2024
Figures by year
YearPrivate raises (Form D)Total
2024$50.0M$50.0M
2023$30.2M$30.2M

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

  1. Mar 13, 2024Raised $50 million in a private offering of equity17 Form D: 25 investors so far Form D
  2. Mar 3, 2023Raised $30.2 million in a private offering of equity49 Form D: 20 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 80. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Nantahala Capital Management, LLC2,802,894$13.1M0.4%+1,863,692
BlackRock, Inc.1,413,381$6.6M0.0%+1,377,478
Vanguard Capital Management LLC1,071,481$5.0M0.0%+260,051
Octagon Capital Advisors LP1,000,000$4.7M0.4%No change
Geode Capital Management, LLC564,019$2.6M0.0%+360,275
Vivo Capital, LLC550,000$2.6M0.2%−1,239,916
Marshall Wace, Llp547,862$2.6M0.0%+392,924
Logos Global Management LP473,563$2.2M0.1%No change
State Street Corp450,162$2.1M0.0%+370,135
Diametric Capital, LP374,132$1.8M0.2%+293,770
J. Goldman & Co LP327,345$1.5M0.1%New
Diadema Partners LP303,676$1.4M0.5%+197,593
Millennium Management LLC271,456$1.3M0.0%−1,127,892
Dauntless Investment Group, LLC214,000$1.0M1.7%+66,913
Citigroup Inc182,654$856.6K0.0%+182,653
Northern Trust Corp181,930$853.3K0.0%+145,993
Vanguard Portfolio Management LLC169,196$793.5K0.0%New
Susquehanna International Group, Llp160,039$750.6K0.0%−39,180
Jump Financial, LLC153,000$717.6K0.0%New
Vanguard Fiduciary Trust Co148,965$698.6K0.0%+47,891
Goldman Sachs Group Inc145,304$681.5K0.0%+118,211
Dimensional Fund Advisors LP143,052$678.0K0.0%No change
Seven Fleet Capital Management LP103,400$521.1K0.1%+47,700
Caption Management, LLC110,000$515.9K0.0%New
Morgan Stanley109,645$514.2K0.0%−78,537

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Unicycive Therapeutics, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARUnicycive Therapeutics, Inc.1
  • CIK0001766140
  • Employer ID (EIN)81-36386923
  • Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; not a shell company3
  • Incorporated inDelaware3
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address1975 W. El Camino Real, Suite 204, Mountain View, CA 940401
  • Phone650-384-06421
  • Shares outstanding27,855,257 as of Aug 12, 20269
  • Public float$64.3M as of Jun 30, 20253
  • AuditorGRASSI & CO., CPAs, P.C., Jericho, New York PCAOB ID 606; no auditor attestation of internal control over financial reporting3
  • On EDGAR sinceMar 4, 20191
  • Filings306 in all: 8-K (70), 4 (49), SCHEDULE 13G/A (26), 10-Q (16), CORRESP (16), SC 13G/A (12), DEFA14A (11), SC 13G (11)1
    All 35 form types

    3 (10), UPLOAD (10), 4/A (9), EFFECT (7), 10-K (5), D (5), DEF 14A (5), S-1/A (5), S-3 (5), ARS (4), DRSLTR (4), S-8 (4), DRS/A (3), PRE 14A (3), 424B5 (2), SCHEDULE 13G (2), SEC STAFF LETTER (2), 144 (1), 424B3 (1), 424B4 (1), 8-A12B (1), 8-K/A (1), CERT (1), DRS (1), NT 10-Q (1), POS AM (1), S-1 (1)

  • Latest filingsAnnual report (10-K) Mar 30, 2026
    Quarterly report (10-Q) Aug 12, 2026
    Proxy statement (DEF 14A) Apr 30, 2026
    Latest 8-K (8-K) Sep 29, 2026

Securities registered for trading

ClassSymbolExchange
Common stock, par value $0.001 per shareUNCYNasdaq

From the cover page of the 10-K filed Mar 30, 2026 (Section 12(b) of the Exchange Act).3

Risk factors and legal proceedings

The risks Unicycive Therapeutics, Inc. names in Item 1A of its 10-K filed Mar 30, 2026: 55 risks under these headings, as written.3

  • Risks Related to our Financial Position and Need for Capital
  • We have generated no product revenue to date and our future profitability is uncertain.
  • If we fail to obtain the capital necessary to fund our operations, we will be unable to continue or complete our product development and you will likely lose your entire investment.
  • We may consider strategic alternatives in order to maximize stockholder value, including financings, strategic alliances, acquisitions or the possible sale of our business. We may not be able to identify or consummate any suitable strategic alternatives.
  • Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our product candidates on unfavorable terms to us.
  • You will experience dilution, subordination of stockholder rights, preferences, and privileges, and decrease in market price of our common stock as a result of our private placement financing in March 2023
  • Our cash could be adversely impacted if a financial institution with which we have deposits or other accounts fails.
  • Risks Related to Our Business
  • The marketing approval process of the FDA is lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain marketing approval for our current product candidates and future product candidates we intend to develop, our business will be substantially harmed.
  • We may encounter substantial delays in completing our clinical studies which in turn will require additional costs, or we may fail to demonstrate adequate safety and efficacy to the satisfaction of applicable regulatory authorities.
  • If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals, we will not be able to commercialize, or will be delayed in commercializing, our product candidates and our ability to generate revenue will be impaired.
  • Modifications to our products may require new NDA approvals.
The other 45 risks
  • Additional delays to the completion of clinical studies may result from modifications being made to the protocol during the clinical trial, if such modifications are warranted and/or required by the occurrences in the given trial.
  • There can be no assurance that the data generated from our clinical trials using modified protocols will be acceptable to the FDA or other regulatory authorities.
  • Conducting successful clinical studies may require the enrollment of large numbers of patients, and suitable patients may be difficult to identify and recruit.
  • The future results of our current or future clinical trials may not support our product candidates claims or may result in the discovery of unexpected adverse side effects.
  • Adverse events involving our products may lead the FDA or other regulatory authorities to delay or deny clearance for our products or result in product recalls that could harm our reputation, business and financial results.
  • Even if our product candidates receive marketing approval, they may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.
  • Even if we are able to commercialize our product candidates, such products may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, which would harm our business.
  • Any product candidate for which we obtain marketing approval could be subject to marketing restrictions or withdrawal from the market and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our products.
  • We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.
  • Our reliance on third parties heightens the risks faced by our business.
  • We intend to rely on third parties to conduct our clinical trials and to conduct some aspects of our research and pre-clinical testing and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, research or testing.
  • Upon commercialization of our products, we may be dependent on third parties to market, distribute and sell our products.
  • We have no experience manufacturing product candidates on a clinical or commercial scale and will be dependent on third parties for the manufacture of our product candidates. If we experience problems with any of these third parties or their subcontractors or vendors, they could delay clinical development or marketing approval of our product candidates or our ability to sell any approved products.
  • We may have conflicts with our partners that could delay or prevent the development or commercialization of our current and future product candidates.
  • Our products will face significant competition, and if they are unable to compete successfully, our business will suffer.
  • Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop.
  • We may engage in acquisitions that could disrupt our business, cause dilution to our stockholders or reduce our financial resources.
  • Security threats to our information technology infrastructure and/or our physical buildings could expose us to liability and damage our reputation and business.
  • We will need to grow the size of our organization in the future, and we may experience difficulties in managing this growth.
  • Our future success depends on our ability to retain our executive officers and to attract, retain and motivate qualified personnel.
  • Inadequate funding for the FDA, the U.S. Securities and Exchange Commission (“SEC”) and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.
  • Risks Related to Our Intellectual Property
  • Our UNI 494 product candidate is subject to an exclusive license agreement. If we fail to meet our obligations and the license is terminated, we may not be able to continue to develop our product candidates.
  • It is difficult and costly to protect our proprietary rights, and we may not be able to ensure their protection. If our patent position does not adequately protect our product candidates, others could compete against us more directly, which would harm our business, possibly materially.
  • If we fail to comply with our obligations in the agreements under which we may license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose rights that are important to our business.
  • We may infringe the intellectual property rights of others, which may prevent or delay our product development efforts and stop us from commercializing or increase the costs of commercializing our product candidates.
  • If we are not able to adequately prevent disclosure of trade secrets and other proprietary information, the value of our technology and product could be significantly diminished.
  • We may be subject to claims that our employees or consultants have wrongfully used or disclosed alleged trade secrets.
  • Our intellectual property may not be sufficient to protect our product candidates from competition, which may negatively affect our business as well as limit our partnership or acquisition appeal.
  • Risks Related to Healthcare Compliance and Other Regulations
  • If we fail to comply with healthcare regulations, we could face substantial enforcement actions, including civil and criminal penalties and our business, operations and financial condition could be adversely affected.
  • Our, or our partners’, failure to obtain or maintain adequate coverage, pricing and reimbursement for oxylanthanum carbonate (OLC), if approved, or any other future approved products, could have a material adverse effect on our or our collaboration partners’ ability to sell such approved products profitably and otherwise have a material adverse impact on our business.
  • Healthcare Reform in the United States.
  • Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could cause significant liability for us and harm our reputation.
  • We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws and anti-money laundering laws and regulations. Compliance with these legal standards could impair our ability to compete in domestic and international markets. We can face criminal liability and other serious consequences for violations, which can harm our business.
  • Risks Related to Owning our Common Stock
  • The price of our common stock may fluctuate substantially.
  • We do not intend to pay cash dividends on our shares of common stock so any returns will be limited to the value of our shares, except we have agreed to pay cash dividends in the event oxylanthanum carbonate is approved by the FDA and commercial sales is commenced.
  • Market and economic conditions may negatively impact our business, financial condition and share price.
  • If securities or industry analysts do not publish research or reports, or publish unfavorable research or reports about our business, our stock price and trading volume may decline.
  • If we fail to comply with the continued listing requirements of the Nasdaq Capital Market, our common stock may be delisted and the price of our common stock and our ability to access the capital markets could be negatively impacted.
  • Because certain of our stockholders control a significant number of shares of our common stock, they may have effective control over actions requiring stockholder approval.
  • We are an “emerging growth company” and will be able to avail ourselves of reduced disclosure requirements applicable to emerging growth companies, which could make our common stock less attractive to investors.
  • We may be at risk of securities class action litigation.
  • Our amended and restated certificate of incorporation (“Amended and Restated Certificate of Incorporation”) and our amended and restated bylaws (the “Amended and Restated Bylaws”), and Delaware law may have anti-takeover effects that could discourage, delay or prevent a change in control, which may cause our stock price to decline.
  • Financial reporting obligations of being a public company in the U.S. are expensive and time-consuming, and our management will be required to devote substantial time to compliance matters.
  • Our Amended and Restated Certificate of Incorporation, provides that the Court of Chancery of the State of Delaware will be the sole and exclusive forum for substantially all disputes between the Company and its stockholders, which could limit stockholders’ ability to obtain a favorable judicial forum for disputes with the Company or its directors, officers or employees.
  • Failure to maintain effective internal controls could cause our investors to lose confidence in us and adversely affect the market price of our common stock. If our internal controls are not effective, we may not be able to accurately report our financial results or prevent fraud.

Legal proceedings

On August 15, 2025, a putative shareholder class action complaint captioned Elkhodari v. Unicycive Therapeutics, Inc., et al., Case No. 3:25-cv-06923-JD (the “Securities Class Action”), was filed in the U.S. District Court for the Northern District of California (“Northern District of California”), naming the Company and certain current officers and/or directors of the Company as defendants. The lawsuit generally alleges that the Company made material misrepresentations and/or omissions of material fact relating to the Company’s manufacturing of oxylanthanum carbonate (“OLC”) and the approval prospects of its New Drug Application for OLC for the treatment of hyperphosphatemia in CKD patients on dialysis in violation of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder. The putative class action is brought on behalf of persons or entities who purchased or otherwise acquired the Company’s securities between March 29, 2024, and June 27, 2025, inclusive, and seeks unspecified monetary damages on behalf of the putative class and an award of costs and expenses, including attorneys’ fees. On January 27, 2026, Plaintiff filed an amended complaint. On March 13, 2026, defendants filed their motion to dismiss the amended complaint. . At this early stage of the proceedings, the Company is unable to make any prediction regarding the outcome of the Securities Class Action.

The opening of Item 3, Legal Proceedings.3

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
    SEC EDGAROther events
  20. 20
  21. 21
    SEC EDGAROther events
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
    SEC EDGAROther events
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49